Revvity Shareholders Re-Elect Board, Approve Bylaw Change; Exec Stock Retention Proposal Fails

Key Points

• All 10 director nominees were re-elected to one-year terms expiring in 2027, with each nominee receiving at least 91% of votes cast.
• Shareholders approved a bylaw amendment allowing holders of 25% of outstanding stock to call a special meeting, the proposal passing with roughly 99% of votes cast.
• A shareholder proposal to require named executives to retain 25% of net after-tax shares until retirement failed (about 77% against), while the advisory say-on-pay passed (~96%) and Deloitte was ratified as auditor (~99%).

Revvity NYSE: RVTY held its 2026 Annual Meeting of Shareholders virtually via live audio webcast, with General Counsel and Secretary Joel Goldberg serving as host and President and CEO Prahlad Singh presiding over the formal business of the meeting.

Goldberg reported that holders of approximately 104 million shares, representing about 93% of the company’s common stock entitled to vote, were present or represented by proxy, establishing a quorum. Singh also noted the board had set March 2, 2026 as the record date for determining shareholders entitled to vote at the meeting, which he said is held on the fourth Tuesday in April each year.

Board nominees introduced and elected

Before the vote, Singh reviewed the qualifications of the director nominees standing for re-election, including Non-Executive Chairman Alexis P. Michas, who Singh described as the founder and managing partner of Juniper Investment Company, LLC and a board member since 2001. Singh also introduced:

• Peter Barrett, a partner at Atlas Venture, first elected to the board in 2012
• Samuel R. Chapin, retired executive vice chairman of Bank of America Merrill Lynch, who joined the board in 2016
• Michael A. Klobuchar, chief operating officer of Eikon Therapeutics Inc., who joined in 2024
• Michelle McMurry-Heath, founder and CEO of BioTechquity Clinical, who joined in 2022
• Sophie V. Vandebroek, former vice president for emerging technology partnerships at IBM, who joined in 2024
• Michel Vounatsos, former CEO of Biogen, who has served on the board since 2020
• Frank Witney, former CEO of Affymetrix, who joined in 2016
• Pascale Witz, founder and president of PWH Advisors, who joined in 2017
• Prahlad R. Singh, president and CEO

On the first proposal, shareholders voted to elect 10 directors for one-year terms expiring at the 2027 annual meeting. Goldberg presented preliminary results showing the director slate passed, with each nominee receiving “the affirmative vote of at least 91% of the votes cast.”

Auditor ratification approved

Shareholders also voted on ratifying the Audit Committee’s selection of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the current fiscal year. Singh noted that Erika Ordway, a partner at Deloitte & Touche, attended and was available to answer questions regarding the firm’s function as auditor.

Goldberg reported the auditor ratification proposal passed with an affirmative vote of approximately 99% of votes cast.

Advisory “say-on-pay” supported

The third proposal sought shareholder approval, on a non-binding advisory basis, of executive compensation for the company’s named executive officers, as disclosed in the proxy statement. Goldberg said the proposal passed with an affirmative vote of approximately 96% of votes cast.

Bylaw change allowing 25% holders to call special meetings passes

Shareholders also approved a management proposal to amend the company’s amended and restated bylaws to allow shareholders owning 25% of the company’s stock to call a special meeting of shareholders. Goldberg reported the bylaw amendment passed with an affirmative vote of approximately 99% of votes cast.

Shareholder proposal on executive stock retention fails

The meeting also included a shareholder proposal related to executive stock ownership, presented by shareholder proponent John Chevedden. Chevedden asked the board to adopt a policy requiring the five named executive officers to retain a “significant percentage” of stock acquired through equity pay programs until retirement, and to report back to shareholders in the next annual meeting proxy.

Chevedden recommended a retention requirement of 25% of net after-tax shares and said the policy should prohibit hedging transactions for shares subject to the policy. He argued that holding requirements would better align executives with long-term performance, and referenced Revvity’s stock price, saying it was $203 in 2021 and “only $86 now.”

Singh thanked Chevedden and referred shareholders to the company’s response in the proxy statement. Goldberg reported the proposal failed, with approximately 77% of votes cast against it.

After concluding the formal items, Singh declared the meeting adjourned and thanked shareholders for attending and for their continued support of Revvity.

About Revvity NYSE: RVTY

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.